News

Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate

Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate

Curetis’ Subsidiary Ares Genetics Teams Up with Leading

Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate

HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus

AOP Orphan announces positive CHMP opinion for Ropeginterferon alfa-2b/BESREMi®

AddLife acquires Austrian Biomedica – international expansion on 13 new markets

Small but versatile – Key players in the marine nitrogen cycle can utilize cyanate and urea

Valneva and HOOKIPA Sign a Collaboration and Manufacturing Agreement

AOP Orphan announces three-year results on Ropeginterferon alfa-2b in Polycythemia Vera at ASH

AWARD FOR PHAGE THERAPY: PHAGOMED WINS AUSTRIAN ENTREPRENEURSHIP AWARD PHÖNIX

EANS-Adhoc: Marinomed Biotech AG suspends offer period of the current IPO

HOOKIPA and DarwinHealth Enter into a Research Collaboration and License Agreement

VIENNESE BIOTECH COMPANY MARINOMED DEMONSTRATES THE BENEFITS OF ITS PATENTED MARINOSOLV® TECHNOLOGY

Arsanis and X4 Pharmaceuticals Agree to Merger

ERC consolidator grant for Kikuë Tachibana

Study on parasites in dog faeces comes to surprising conclusion

Brigitte Ederer joins the Supervisory Board of Marinomed

EUR 96 million of EIF and aws finance for innovative businesses in Austria

EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS